The measurement of fractionated metanephrines in a 24-hour urine collection is a clinical diagnostic tool employed to detect catecholamine-secreting tumors, such as pheochromocytomas and paragangliomas. This test quantifies the levels of metanephrine and normetanephrine, which are metabolites of epinephrine (adrenaline) and norepinephrine (noradrenaline), respectively. Elevated levels of these metabolites in urine can indicate excessive catecholamine production, a hallmark of these tumors.
Accurate diagnosis is crucial because untreated catecholamine-secreting tumors can lead to severe hypertension, cardiac arrhythmias, and even stroke. The historical development of this test has significantly improved the detection and management of these potentially life-threatening conditions. Early and accurate identification facilitates timely intervention, including surgical resection or medical management to control catecholamine excess.
